Low dose liraglutide in Indian patients with type 2 diabetes in the real world setting

Liraglutide, a human glucagon-like peptide-1 receptor agonist, decreases glycosylated hemoglobin and causes weight loss. However, the cost of therapy and gastrointestinal side- effects such as nausea and diarrhea are important impediments to adherence and long-term compliance. We assessed the effica...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanyal, Debmalya, Majumdar, Anirban
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830340/
https://www.ncbi.nlm.nih.gov/pubmed/24251194
http://dx.doi.org/10.4103/2230-8210.119629
_version_ 1782291480670371840
author Sanyal, Debmalya
Majumdar, Anirban
author_facet Sanyal, Debmalya
Majumdar, Anirban
author_sort Sanyal, Debmalya
collection PubMed
description Liraglutide, a human glucagon-like peptide-1 receptor agonist, decreases glycosylated hemoglobin and causes weight loss. However, the cost of therapy and gastrointestinal side- effects such as nausea and diarrhea are important impediments to adherence and long-term compliance. We assessed the efficacy, safety and tolerability of low dose (0.6 mg) liraglutide in obese uncontrolled longstanding type 2 diabetes in Indian patients. Low dose liraglutide improved glycemic control and decreased weight. However, there was a significant drop out because of gastrointestinal intolerance and financial constraints.
format Online
Article
Text
id pubmed-3830340
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-38303402013-11-18 Low dose liraglutide in Indian patients with type 2 diabetes in the real world setting Sanyal, Debmalya Majumdar, Anirban Indian J Endocrinol Metab Brief Communication Liraglutide, a human glucagon-like peptide-1 receptor agonist, decreases glycosylated hemoglobin and causes weight loss. However, the cost of therapy and gastrointestinal side- effects such as nausea and diarrhea are important impediments to adherence and long-term compliance. We assessed the efficacy, safety and tolerability of low dose (0.6 mg) liraglutide in obese uncontrolled longstanding type 2 diabetes in Indian patients. Low dose liraglutide improved glycemic control and decreased weight. However, there was a significant drop out because of gastrointestinal intolerance and financial constraints. Medknow Publications & Media Pvt Ltd 2013-10 /pmc/articles/PMC3830340/ /pubmed/24251194 http://dx.doi.org/10.4103/2230-8210.119629 Text en Copyright: © Indian Journal of Endocrinology and Metabolism http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Communication
Sanyal, Debmalya
Majumdar, Anirban
Low dose liraglutide in Indian patients with type 2 diabetes in the real world setting
title Low dose liraglutide in Indian patients with type 2 diabetes in the real world setting
title_full Low dose liraglutide in Indian patients with type 2 diabetes in the real world setting
title_fullStr Low dose liraglutide in Indian patients with type 2 diabetes in the real world setting
title_full_unstemmed Low dose liraglutide in Indian patients with type 2 diabetes in the real world setting
title_short Low dose liraglutide in Indian patients with type 2 diabetes in the real world setting
title_sort low dose liraglutide in indian patients with type 2 diabetes in the real world setting
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830340/
https://www.ncbi.nlm.nih.gov/pubmed/24251194
http://dx.doi.org/10.4103/2230-8210.119629
work_keys_str_mv AT sanyaldebmalya lowdoseliraglutideinindianpatientswithtype2diabetesintherealworldsetting
AT majumdaranirban lowdoseliraglutideinindianpatientswithtype2diabetesintherealworldsetting

Ejemplares similares